Physician profile
Jamie Holmes
NPI 1265976773
$3,682.86
in general payments reported to CMS, 2019-2025
34 companies · $516 in 2025
The $516 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $702 · 2022: $471 · 2023: $938 · 2024: $1,056 · 2025: $516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,510.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,510.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $700.86 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $604.81 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $377.74 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Dexcom, INC. | $257.03 | 2024-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $243.58 | 2021-2025 | |
| Abbott Laboratories | $218.29 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Abbvie INC. | $161.46 | 2021-2022 | |
| Amgen INC. | $155.55 | 2021-2025 | Repatha, Otezla, Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.86 | 2023 | Jardiance, Synjardy |
| Collegium Pharmaceutical, INC. | $80.86 | 2021 | |
| Exact Sciences Corporation | $68.11 | 2023-2024 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.28 | 2021-2023 | Xifaxan |
| Redhill Biopharma INC. | $60.91 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $50.19 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $46.90 | 2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biodelivery Sciences International, INC. | $46.50 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $39.79 | 2023 | |
| Antares Pharma, INC. | $37.07 | 2025 | Xyosted |
| Si-Bone, INC. | $32.00 | 2021 | |
| Pacira Therapeutics, INC. | $31.94 | 2021 | |
| Lundbeck LLC | $31.42 | 2021-2023 | Rexulti |
| Scilex Pharmaceuticals INC. | $29.92 | 2021 | |
| Axsome Therapeutics, INC. | $28.34 | 2024 | Sunosi |
| Eisai INC. | $23.66 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $22.96 | 2023 | Eliquis |
| Shield Therapeutics INC | $21.54 | 2024 | |
| Baudax Bio INC. | $18.71 | 2021 | |
| Astellas Pharma US INC | $17.68 | 2021 | |
| Sumitomo Pharma America, INC. | $15.70 | 2025 | Gemtesa |
| Xeris Pharmaceuticals, INC. | $14.16 | 2024 | Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $13.59 | 2021 | |
| Merck Sharp & Dohme LLC | $13.26 | 2021 | |
| Phathom Pharmaceuticals, INC. | $13.07 | 2024 | Voquezna |
| Supernus Pharmaceuticals, INC. | $11.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Holmes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.